ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Short Interest Update

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was the target of a significant growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily trading volume, of 253,300 shares, the short-interest ratio is presently 9.3 days.

ANI Pharmaceuticals Stock Performance

Shares of ANIP stock opened at $54.21 on Tuesday. The company has a debt-to-equity ratio of 1.52, a current ratio of 2.74 and a quick ratio of 1.97. The company’s fifty day moving average price is $57.26 and its two-hundred day moving average price is $59.47. The firm has a market capitalization of $1.14 billion, a P/E ratio of -98.56 and a beta of 0.73. ANI Pharmaceuticals has a 12 month low of $52.50 and a 12 month high of $70.81.

ANI Pharmaceuticals (NASDAQ:ANIP) last released its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 EPS for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The business had revenue of $148.30 million for the quarter, compared to analysts’ expectations of $144.37 million. During the same quarter in the previous year, the firm posted $1.05 earnings per share. The company’s revenue was up 12.5% compared to the same quarter last year. On average, research analysts anticipate that ANI Pharmaceuticals will post 3.87 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have issued reports on the company. Truist Financial boosted their price target on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research report on Tuesday, October 22nd. Raymond James increased their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target on the stock. StockNews.com downgraded shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, September 7th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, December 11th. Two equities research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

Insider Activity at ANI Pharmaceuticals

In related news, SVP Krista Davis sold 1,000 shares of the business’s stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total value of $60,000.00. Following the completion of the sale, the senior vice president now directly owns 49,059 shares in the company, valued at approximately $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Nikhil Lalwani sold 33,481 shares of the stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at approximately $21,478,220.22. This represents a 8.29 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 42,231 shares of company stock valued at $2,434,286. Company insiders own 12.70% of the company’s stock.

Institutional Trading of ANI Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Global Alpha Capital Management Ltd. boosted its holdings in ANI Pharmaceuticals by 1.8% in the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company’s stock worth $32,005,000 after purchasing an additional 9,500 shares during the period. Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals in the 2nd quarter worth about $228,000. Thompson Siegel & Walmsley LLC boosted its holdings in shares of ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company’s stock valued at $13,731,000 after buying an additional 34,416 shares during the period. Thrivent Financial for Lutherans grew its position in shares of ANI Pharmaceuticals by 2.3% during the 3rd quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company’s stock valued at $777,000 after buying an additional 299 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in ANI Pharmaceuticals by 15.4% during the second quarter. Renaissance Technologies LLC now owns 156,802 shares of the specialty pharmaceutical company’s stock worth $9,985,000 after acquiring an additional 20,900 shares during the period. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.